Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Outcomes of Treatment With Topical Ivermectin vs Metronidazole in Patients With Rhinophyma
TAKE-HOME MESSAGE
- This randomized controlled trial evaluated the efficacy and tolerability of ivermectin 1% cream applied once or twice daily versus metronidazole 0.75% gel applied twice daily for 12 weeks in 50 patients with mild/moderate inflamed rhinophyma. Treatment with ivermectin twice daily resulted in statistically superior improvement in erythema and papules/pustules at 8 and 12 weeks compared with treatment with ivermectin once daily and metronidazole twice daily. In addition, 60% of the patients treated with ivermectin 1% cream twice daily achieved a clear/almost clear status. All treatments were well-tolerated.
- This clinical trial showed that twice-daily ivermectin 1% cream is more effective in treating patients with mild to moderate inflamed rhinophyma compared with once-daily ivermectin 1% cream or twice-daily metronidazole 0.75% gel.
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersInflamed rhinophyma is a diagnostic phenotype of rosacea according to the ROSacea COnsensus panel, characterized by erythema, prominent dilated pilosebaceous pores, and recurrent papules/pustules. Its management is challenging, as no specific drug is available to date. The aim of our randomized controlled trial was to evaluate efficacy and tolerability of ivermectin (IVM) 1% cream applied once or twice daily versus metronidazole (MTZ) 0.75% gel twice daily (both labeled for inflammatory rosacea) for 12 weeks in mild/ moderate inflamed rhinophyma.
Additional Info
Inflamed rhinophyma treated with topical ivermectin: A randomized controlled study
J Am Acad Dermatol 2024 Sep 01;91(3)519-521, F Dall'Oglio, MR Nasca, P Vitale, H Platania, G MicaliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.